We are live on ! Find out more
CKPT

Checkpoint Therapeutics

Delisted

CKPT was delisted on the 29th of May, 2025.

47 hedge funds and large institutions have $17.2M invested in Checkpoint Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 6

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

38% more call options, than puts

Call options by funds: $694K | Put options by funds: $503K

36% more capital invested

Capital invested by funds: $12.6M → $17.2M (+$4.6M)

4% more funds holding

Funds holding: 4547 (+2)

1.1% more ownership

Funds ownership: 16.26%17.36% (+1.1%)

Holders
47
Holders Change
+2
Holders Change %
+4.44%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
24
Reduced
6
Closed
4
Calls
$694K
Puts
$503K
Net Calls
+$191K
Net Calls Change
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
HGERS
51
Householder Group Estate & Retirement Specialist
Arizona
+$462 +200 New

CKPT Hedge Fund Activity: Q3 2024 in Review

47 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2024, worth a combined $17.2M — up 36% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CKPT positions and 4 closed out — a net gain of 3 holders — while 24 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, adding an estimated $3.18M. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $493K sold.

  • 47 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2024, up from 45 in Q2 2024.
  • Funds reported $17.2M of Checkpoint Therapeutics stock for Q3 2024, up 36% quarter-over-quarter.
  • 7 funds opened new Checkpoint Therapeutics positions in Q3 2024 and 4 closed out, a net change of +3 holders.
  • The largest Checkpoint Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $3.18M added.
  • The largest Checkpoint Therapeutics seller in Q3 2024 was B. Riley Wealth Advisors, an estimated $493K sold.

Based on aggregated 13F filings for Q3 2024.